Montana Primary Care Association

Percentage of women 21–64 years of age who were screened for cervical cancer using either of the following criteria:

• Women age 21-64 who had cervical cytology performed every 3 years.
• Women age 30-64 who had cervical cytology/human papillomavirus (HPV) cotesting performed every 5 years.

Denominator: Women 23 through 64 years of age with a medical visit during the measurement period.
Numerator: Women with one or more screenings for cervical cancer. Appropriate screenings are defined by any one of the following criteria:

• Cervical cytology performed during the measurement period or the 2 years prior to the measurement period for women who are at least 21 years old at the time of the test.
• Cervical cytology/HPV co-testing performed during the measurement period or the 4 years prior to the measurement period for women who are at least 30 years old at the time of the test.

QDI 2023 Statewide Goal: 65%

Diabetes Management: Hemoglobin A1c (HbA1c) Poor Control (>9 percent) (CMS122v7)
Percentage of patients 18–75 years of age with diabetes who had hemoglobin A1c (HbA1c) greater than 9.0 percent during the measurement period.

Denominator: Patients 18 through 75 years of age with diabetes with a medical visit during the measurement period.
Numerator: Patients whose most recent HbA1c level performed during the measurement year is greater than 9.0 percent and patients who had no test conducted during the measurement period.

QDI 2023 Statewide Goal: 15%

Colorectal Cancer Screening (CMS130v7)
Percentage of adults 50–75 years of age who had appropriate screening for colorectal cancer.

Denominator: Patients 50 through 75 years of age with a medical visit during the measurement period.
Numerator: Patients with one or more screenings for colorectal cancer. Appropriate screenings are defined by any one of the following criteria:

• Fecal occult blood test (FOBT) during the measurement period.
• Fecal immunochemical test (FIT)- deoxyribonucleic acid (DNA) during the measurement period or the 2 years prior to the measurement period.
• Flexible sigmoidoscopy during the measurement period or the 4 years prior to the measurement period.
• Computerized tomography (CT) colonography during the measurement period or the 4 years prior to the measurement period.
• Colonoscopy during the measurement period or the 9 years prior to the measurement period.

QDI 2023 Statewide Goal: 55%

Colorectal Cancer FIT Kit Resources.

Breast Cancer Screening (CMS125v7)
Percentage of women 50-74 years of age who had a mammogram to screen for breast cancer.

Denominator: Women 51-74 years of age with a visit during the measurement period.
Numerator: Women with one or more mammograms during the measurement period or the 15 months prior to the measurement period.

QDI 2023 Statewide Goal: 55% 

Depression Screening and Follow-up (CMS 2v9)
Patients aged 12 years and older screened for depression on the date of the qualifying encounter or 14 days prior to the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the qualifying encounter.

Denominator:

All patients aged 12 years and older at the beginning of the measurement period with at least one eligible encounter during the measurement period.

• Age >= 12 at the  start of the measurement period.
• Measure qualifying visit in the last 12 months (See value set tab and technical specifications for qualifying visit codes).

Numerator:

Patients screened for depression on the date of a qualifying encounter or 14 days prior to the date of a qualifying encounter using an age appropriate standardized depression screening tool AND if positive, a follow up plan is documented at the qualifying encounter.

• Standardized depression screening in the last 12 months at, or within 14 days of, a qualifying encounter.*
  • Negative Depression Screening Result (PHQ-2 < 3 or PHQ-9 < 10 or negative result from a standardized screening tool) in the last 12 months.

OR

• Positive Depression Screening Result (PHQ-2 >= 3 or PHQ-9 >= 10 or positive result from a standardized screening tool) in the last 12 months.

AND

• Follow-up at a qualifying depression screening encounter must include one or more of the following:
  • Additional evaluation for depression such as: psychiatric interview, psychiatric evaluation, or assessment for bipolar disorder.
  • Suicide Risk Assessment.
  • Referral to a practitioner who is qualified to diagnose and treat depression.
  • Pharmacological interventions (prescription of medication).
  • Other interventions or follow-up for the diagnosis or treatment of depression, e.g. depression self-management.

*This measure looks for the most recent depression screening, which is defined as a depression screening at or within 14 days of a qualifying encounter. Depression screenings that are conducted at a non-qualifying encounter and are not performed within 14 days of a qualifying encounter are not counted toward this measure and have no impact on the numerator compliance of a patient.

QDI 2023 Statewide Goal: 80%

Medication for Opioid Use Disorder (MOUD)
Number of waived providers and patients treated with MOUD by a waived provider per center.